This message was sent to ##Email##
|
|
|
|
|
| |
Yale University via ScienceDaily
Yale experts and their partners in a national research consortium have identified several genes and gene clusters associated with the immune response to flu vaccination. The findings point to the prospect of using genetic profiles to predict individual responses to the flu vaccine.
The research was published Aug. 25 in Science Immunology.
READ MORE
Scientific American
Thirty million American women and men will struggle with eating disorders in their lifetime, and these life-threatening conditions have a higher mortality rate than any other psychiatric illness. For example, someone struggling with anorexia for five years has a 5 percent, or 1 in 20 chance, of dying.
READ MORE
The New York Times
Bob Hutchinson’s mother told him and his siblings almost nothing about her family, no matter how often they asked. “She was good at brushing people off,” said Mr. Hutchinson, 60.
Growing up, there were no photos of his mother as a child in the home, or of her own parents. She said that she was an only child, that her parents were dead. Her heritage, she claimed, was Italian and Swedish.
READ MORE
ABC News
Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors.
Kite's portfolio of potential treatments includes one for the blood cancer lymphoma that could receive U.S. regulatory approval later this year.
READ MORE
Fox News
It’s a sentence no family wants to hear: “Your child has cancer.”
However, it may be a reality for many, with thousands of new cases expected to be diagnosed this year. Sept. 1 marks the beginning of Childhood Cancer Awareness Month. Here are some key figures.
READ MORE
STAT News
Parkinson’s disease can happen when some of a person’s dopamine-producing brain cells die, so replacing those neurons could be an effective treatment. Administering dopamine is part of currently accepted treatment, but over time the treatment has less effect as neurons die off and the side effects become difficult to manage. Injecting neurons created from stem cells into the brain may relieve Parkinson’s symptoms, according to a new study in monkeys.
READ MORE
University of Pennsylvania via ScienceDaily
Bone marrow contains hematopoetic stem cells, the precursors to every blood cell type. These cells spring into action following bone marrow transplants, bone marrow injury and during systemic infection, creating new blood cells, including immune cells, in a process known as hematopoiesis.
READ MORE
| | EMERGING MEDICAL TECHNOLOGIES |
Forbes
Bruce Lee writes: Back to reality ... sort of. Recently, I attended the Games for Change Festival at the Parsons School of Design at The New School in New York City. The 14th installment of this annual event that brings together people who make video games to help society, people, and health also included a one-day Virtual Reality for Change Summit on August 2. And this VR summit showed just how much of a reality VR for healthcare is becoming.
READ MORE
| | BIOTECH/DIAGNOSTICS/PERSONALIZED MEDICINE |
AJMC.com
Personalized medicine is a broad term that encompasses a movement toward use of specific biomarkers and tests to tailor therapy for each patient to optimize outcomes. For health systems, personalized medicine has the potential to improve the efficiency of diagnosis and enable prescribing of the right medications for each patient. In its current form, personalized medicine is largely limited to the use of specific genetic biomarkers to select treatments for subgroups of patients.
READ MORE
Health IT Analytics
The healthcare big data market is set another in a long series of revolutions as life science, precision medicine, consumer technology, and “omics” companies start to infuse their influence into a rapidly changing analytics environment.
As more traditional clinical and financial datasets are joined by Internet of Things data, patient-reported outcomes, and a wealth of new genomic, transcriptomic, proteomic, and epigenomic data sources, the industry’s ability to paint extraordinarily detailed portraits of individuals and larger populations will increase exponentially, says Kalorama Information in a new report.
READ MORE
Medical Xpress
In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration approved a personalized cellular therapy developed by the University of Pennsylvania and Children's Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
READ MORE
| | ACCOUNTABLE CARE ORGANIZATIONS |
HealthLeaders Media
Only 23 percent of net patient revenue comes from value-based payments. In three years, that that is expected to more than double to 48 percent. Managing financial risk is a must for healthcare organizations.
With the shift from fee-for-service to value-based payment on the upswing, most finance leaders in the healthcare provider industry are focused on adopting and operating risk-based reimbursement models for medical services.
READ MORE
Modern Healthcare
The CMS is making a more concerted effort to make sure doctors know which patients they're responsible for in Medicare accountable care organizations.
The CMS has updated the Medicare website to allow a beneficiary to list his or her primary-care doctor. If that doctor is in an ACO, the beneficiary would be assigned to both that provider and their ACO starting next year.
READ MORE
| | FDA: NEW TREATMENTS AND TECHNOLOGY |
The Associated Press via CBS News
For the first time, a drug has helped prevent heart attacks by curbing inflammation, a new and very different approach than lowering cholesterol, the focus for many years.
People on the drug also had surprisingly lower cancer death rates, especially from lung cancer. An anti-tumor effect is an exciting possibility, but it needs much more study because the heart experiment wasn't intended to test that.
READ MORE
Forbes
Following years of lobbying and laboratory research on the medical uses of methylenedioxymethamphetamine, or MDMA, the U.S. Food and Drug Administration has decided to move forward with the drug.
Last week, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the FDA has granted Breakthrough Therapy Designation to MDMA for the treatment of post-traumatic stress disorder.
READ MORE
NPR
The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.
Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.
READ MORE
NPR
Congress and the Trump administration could boost insurance coverage by a couple of million people and lower premiums by taking a few actions to stabilize the Affordable Care Act insurance markets, according to a new analysis by the consulting firm Oliver Wyman.
The paper, which lays out a simple blueprint for making insurance more affordable for more people while working within the current health law's structure, comes just days before the Senate Health, Education, Labor and Pensions Committee begins hearings on ways to stabilize markets in the short term.
READ MORE
CBS News
As if there isn't enough to worry about when it comes to finding health insurance, add this item to the list: Medicare Advantage.
Changes in plan structures and a dearth of insurers in rural areas may leave consumers with fewer choices and more confusion in the upcoming Medicare open enrollment period, which begins Oct. 15.
READ MORE
|
| Jazz Pharmaceuticals is proud to announce that VYXEOS has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Please click here for more information. |
| Puma Biotechnology, Inc. today announced that the U.S. FDA has approved NERLYNX™ (neratinib), a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Please click here for more details and the full press release. |
| Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma. The companies announced that the phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (PFS) versus the control arm. Click here to view the full press release. |
| Join Zitter Health Insights’ (ZHI) research panel and earn honoraria - paid directly to you or to your favorite charity. ZHI provides innovative insights that help optimize patient access to pharmaceuticals. We work for and with life science companies, specialty pharmacies and managed healthcare organizations across the US. For nearly 30 years, our syndicated research and expertise have helped customers solve market access challenges. This research helps IDNs exercise greater influence over how the pharmaceutical industry approaches and interacts with them. We are recruiting IDN executives to participate in our research and your knowledge is paramount to providing key stakeholders with insights into the challenging issues involved with pharmaceutical access. We look forward to your participation in this important dialogue. Yes, I’d like to learn more and participate! |
| CVS Health today announced the company will launch Reduced Rx™, a prescription savings program that will offer discounts on certain medications – through CVS Health’s pharmacy benefits manager, CVS Caremark – directly to patients. The program will help patients with high out of pocket costs afford essential medications. Novo Nordisk will participate in the prescription savings program. Through this program, CVS Health and Novo Nordisk will offer Novolin R®, Novolin N® and Novolin 70/30® human insulin at a cost of $25 per 10ml vial, which reflects a potential savings of as much as $100 for cash paying patients. Click here for more information. |
| Intarcia Therapeutics, Inc. is a rapidly emerging biopharmaceutical company committed to developing innovative therapies utilizing the Medici Drug Delivery System™ – therapies that have the potential to transform the prevention and management of serious chronic diseases. Across chronic diseases, medication non-adherence can compromise clinical outcomes and drive excess cost to the healthcare system. Intarcia is working to address this problem through innovative technologies. We invite you to visit our website to learn more. |
| The National Institute for Health and Care Excellence (NICE) issued positive guidance recommending the use of the HeartFlow FFRct Analysis to help determine the cause of stable chest pain in patients. The HeartFlow FFRct Analysis is the first non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, aiding clinicians in selecting an appropriate treatment. Please click here to view the full press release. |
| Last month, Novo Nordisk received approval from the US Food and Drug Administration for the New Drug Application (NDA) for Xultophy® 100/3.6. Xultophy® 100/3.6 is a combination of insulin degludec and liraglutide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin or liraglutide. The FDA has required Novo Nordisk to distribute the safety notice as part of the Xultophy® 100/3.6 REMS program. Click Here for the Letter. Click Here for the fact sheet. |
| Courtagen Life Sciences, Inc., an innovative molecular information company focused on providing genetic diagnoses for neurological conditions through next generation sequencing, offers a broad range of genetic testing panels for epilepsy, including recently-added epiSEEK® Spotlight Panels designed to target genes that have been reported in association with specific phenotypes for epilepsy and seizure disorders. Please click here for more information. |
| New iOn PROGRESS™ Remote Therapy Monitoring system from Acelity marks first continuous monitoring and ready intervention for patients receiving negative pressure wound therapy at home, and supports patient compliance. Non-compliance can lead to unnecessary spending for excessive hospital readmissions ,and unnecessary ER visits. Please click here to review the full press release. |
| Based on published clinical data, Humana, Medical Mutual of Ohio and Preferred One independently determined and published policies stating that Biodesix’ VeriStrat® test can be considered medically necessary for patients with advanced NSCLC. The VeriStrat test provides physicians with prognostic and predictive information to inform treatment of advanced NSCLC, and can facilitate patient-physician conversations about prognosis, life expectancy, and treatment recommendations. Click here for more information. |
Check out JMCM’s new website at www.jmcmpub.org
|
|
Missed last week's issue? See which articles your colleagues read most.
|
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
